Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.46 USD | -2.01% | -15.12% | +65.91% |
05-13 | Atossa Therapeutics Files $100 Million Mixed-Shelf Offering | MT |
05-13 | Atossa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+65.91% | 184M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+46.00% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- ATOS Stock
- News Atossa Therapeutics, Inc.
- Atossa Therapeutics Enrolls 170 Patients in Phase 2 Karisma-Endoxifen Clinical Trial